This journal only 2017, Number 3 Rev Mex Cardiol 2017; 28 (3) Predictors of the progression of metabolic disorders and insulin resistance in patients with arterial hypertension and diabetes mellitus type 2 Bilivol OM, Bobronnikova LR, Al-Trawneh OV Full text How to cite this article Language: English References: 21 Page: 118-123 PDF size: 183.44 Kb. Key words: Arterial hypertension, diabetes mellitus type 2, metabolic disorders, insulin resistance, adipocytokines. ABSTRACT The mechanisms of the metabolic disorders progression were analyzed in patients with concomitant course of arterial hypertension and diabetes mellitus type 2, of which the most significant are the insulin resistance state, disorders of carbohydrate metabolism, development of atherogenic dyslipidemia and systemic inflammation in correlation with the imbalance of adipocytokines, which contributes to high cardiovascular risk. REFERENCES Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. J Nephrol. 2011; 24: 23-34. Shimamoto K, Miura T, Nippon R. Metabolic syndrome. 2009; 67 (4): 771-776. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011; 34 (3): 307-310. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension. Can J Cardiol. 2010; 26 (5): 249-258. Emerging Risk Factors Collaboration1, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375 (9733): 2215-2222. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009; 27: 963-975. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009; 32 (2): 151-156. Aroor RA, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin. 2012; 8 (4): 609-617. Boudina S. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010; 11: 31-39. Zhou J, Qin G. Adipocyte dysfunction and hypertension. Am J Cardiovasc Dis. 2012; 2 (2): 143-149. Mracek T, Gao D, Tzanavari T et al. Downregulation of zinc-α2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-α in adipocytes. J Endocrinol. 2010; 204 (2): 165-172. Gong FY, Zhang SJ, Deng JY, Zhu HJ, Pan H, Li NS et al. Zinc-α2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes (Lond). 2009; 33 (9): 1023-1030. Selva DM, Lecube A, Hernandez C, Baena JA, Fort JM, Simó R. Lower zinc- α2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin Endocrinol Metab. 2009; 94 (11): 4499-4507. Byerley LO, Lee SH, Redmann S, Culberson C, Clemens M, Lively MO. Evidence for a novel serum factor distinct from zinc alpha-2 glycoprotein that promotes body fat loss early in the development of cachexia. Nutrition and Cancer. 2010; 62 (4): 484-494. Olofsson LE, Olsson B, Lystig T, Jacobson P, Jernås M, Sjöholm K et al. Preliminary report: Zn-alpha2-glycoprotein genotype and serum levels are associated with serum lipids. Metabolism: Clinical and Experimental. 2010; 59 (9): 1316-1318. Russell ST, Tisdale MJ. Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse. Int J Obes (Lond). 2011; 35 (3): 345-354. Russell ST, Tisdale MJ. Studies on the anti-obesity activity of zinc-α2-glycoprotein in the rat. Int J Obesity. 2011; 35 (5): 658-665. Zhu HJ, Dong CX, Pan H, Ping XC, Li NS, Dai YF et al. Rs4215 SNP in zinc-α2- glycoprotein gene is associated with obesity in Chinese north Han population. Gene. 2012; 500 (2): 211-215. Stepan H, Philipp A, Roth I, Kralisch S, Jank A, Schaarschmidt W et al. Serum levels of the adipokine zinc-alpha2-glycoprotein are increased in preeclampsia. J Endocrinol Invest. 2012; 35: 562-565. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Abdalla DS, Leite M Jr et al. Is zinc- α2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis? Clin Chim Acta. 2012; 413 (5-6): 616-619. Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P, Montanari A et al. Serum adipokine zinc α2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metabolism. 2012; 61 (1): 37-42.